The GenoType® MTBDRsltest for resistance to second-line anti-tuberculosis drugs (Protocol)

Grant Theron; Jonny Peter; Marinus Barnard; Sarah Donegan; Rob Warren; Karen Steingart; Keertan Dheda; Grant Theron

doi:10.1002/14651858.cd010705

The GenoType® MTBDRsltest for resistance to second-line anti-tuberculosis drugs (Protocol)

Grant Theron
, Jonny Peter
, Marinus Barnard
, Sarah Donegan
, Rob Warren
, Karen Steingart
, Keertan Dheda
, Grant Theron

Clinical Sciences

Liverpool School of Tropical Medicine

Research output: Contribution to journal › Article › peer-review

Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

To obtain summary estimates of the diagnostic accuracy of GenoType® MTBDRsl for detection of resistance to the fluoroquinolones in patient specimens or culture isolates confirmed as TB positive.

To obtain summary estimates of the diagnostic accuracy of GenoType® MTBDRsl for detection of resistance to second-line injectable drugs in patient specimens or culture isolates confirmed as TB positive.

To obtain summary estimates of the diagnostic accuracy of GenoType® MTBDRsl for detection of XDR-TB in patient specimens or culture isolates confirmed as TB positive.

Purpose of index test: GenoType® MTBDRsl used as an initial test replacing phenotypic culture-based DST as the initial test.

We plan to investigate heterogeneity in relation to the reference tests (genetic sequencing, culture-based DST, and culture-based DST followed by genetic sequencing), as well as by type of testing (indirect or direct). We also plan to investigate heterogeneity in relation to HIV status, conditions of the specimens (fresh or frozen, volume of specimen) and patient population (patients suspected of having MDR-TB or XDR-TB).

Original language	English
Article number	CD010705
Pages (from-to)	CD010705
Journal	Cochrane Database of Systematic Reviews
Volume	2013
Issue number	8
DOIs	https://doi.org/10.1002/14651858.cd010705
Publication status	Published - 1 Aug 2013

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1002/14651858.cd010705Licence: CC BY-NC

CD010705-1Final published version, 577 KBLicence: CC BY-NC

Cite this

@article{1ddd86e011b643f69c3e284615ad0eb1,

title = "The GenoType{\textregistered} MTBDRsltest for resistance to second-line anti-tuberculosis drugs (Protocol)",

abstract = "This is the protocol for a review and there is no abstract. The objectives are as follows:To obtain summary estimates of the diagnostic accuracy of GenoType{\textregistered} MTBDRsl for detection of resistance to the fluoroquinolones in patient specimens or culture isolates confirmed as TB positive.To obtain summary estimates of the diagnostic accuracy of GenoType{\textregistered} MTBDRsl for detection of resistance to second-line injectable drugs in patient specimens or culture isolates confirmed as TB positive.To obtain summary estimates of the diagnostic accuracy of GenoType{\textregistered} MTBDRsl for detection of XDR-TB in patient specimens or culture isolates confirmed as TB positive.Purpose of index test: GenoType{\textregistered} MTBDRsl used as an initial test replacing phenotypic culture-based DST as the initial test.We plan to investigate heterogeneity in relation to the reference tests (genetic sequencing, culture-based DST, and culture-based DST followed by genetic sequencing), as well as by type of testing (indirect or direct). We also plan to investigate heterogeneity in relation to HIV status, conditions of the specimens (fresh or frozen, volume of specimen) and patient population (patients suspected of having MDR-TB or XDR-TB).",

author = "Grant Theron and Jonny Peter and Marinus Barnard and Sarah Donegan and Rob Warren and Karen Steingart and Keertan Dheda and Grant Theron",

year = "2013",

month = aug,

day = "1",

doi = "10.1002/14651858.cd010705",

language = "English",

volume = "2013",

pages = "CD010705",

journal = "Cochrane Database of Systematic Reviews",

issn = "1465-1858",

publisher = "John Wiley and Sons Ltd",

number = "8",

}

TY - JOUR

T1 - The GenoType® MTBDRsltest for resistance to second-line anti-tuberculosis drugs (Protocol)

AU - Theron, Grant

AU - Peter, Jonny

AU - Barnard, Marinus

AU - Donegan, Sarah

AU - Warren, Rob

AU - Steingart, Karen

AU - Dheda, Keertan

AU - Theron, Grant

PY - 2013/8/1

Y1 - 2013/8/1

N2 - This is the protocol for a review and there is no abstract. The objectives are as follows:To obtain summary estimates of the diagnostic accuracy of GenoType® MTBDRsl for detection of resistance to the fluoroquinolones in patient specimens or culture isolates confirmed as TB positive.To obtain summary estimates of the diagnostic accuracy of GenoType® MTBDRsl for detection of resistance to second-line injectable drugs in patient specimens or culture isolates confirmed as TB positive.To obtain summary estimates of the diagnostic accuracy of GenoType® MTBDRsl for detection of XDR-TB in patient specimens or culture isolates confirmed as TB positive.Purpose of index test: GenoType® MTBDRsl used as an initial test replacing phenotypic culture-based DST as the initial test.We plan to investigate heterogeneity in relation to the reference tests (genetic sequencing, culture-based DST, and culture-based DST followed by genetic sequencing), as well as by type of testing (indirect or direct). We also plan to investigate heterogeneity in relation to HIV status, conditions of the specimens (fresh or frozen, volume of specimen) and patient population (patients suspected of having MDR-TB or XDR-TB).

AB - This is the protocol for a review and there is no abstract. The objectives are as follows:To obtain summary estimates of the diagnostic accuracy of GenoType® MTBDRsl for detection of resistance to the fluoroquinolones in patient specimens or culture isolates confirmed as TB positive.To obtain summary estimates of the diagnostic accuracy of GenoType® MTBDRsl for detection of resistance to second-line injectable drugs in patient specimens or culture isolates confirmed as TB positive.To obtain summary estimates of the diagnostic accuracy of GenoType® MTBDRsl for detection of XDR-TB in patient specimens or culture isolates confirmed as TB positive.Purpose of index test: GenoType® MTBDRsl used as an initial test replacing phenotypic culture-based DST as the initial test.We plan to investigate heterogeneity in relation to the reference tests (genetic sequencing, culture-based DST, and culture-based DST followed by genetic sequencing), as well as by type of testing (indirect or direct). We also plan to investigate heterogeneity in relation to HIV status, conditions of the specimens (fresh or frozen, volume of specimen) and patient population (patients suspected of having MDR-TB or XDR-TB).

U2 - 10.1002/14651858.cd010705

DO - 10.1002/14651858.cd010705

M3 - Article

SN - 1465-1858

VL - 2013

SP - CD010705

JO - Cochrane Database of Systematic Reviews

JF - Cochrane Database of Systematic Reviews

IS - 8

M1 - CD010705

ER -

The GenoType® MTBDRsltest for resistance to second-line anti-tuberculosis drugs (Protocol)

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this